Cargando…
We Need to Inform COVID-19 Vaccinating Clinics Concerning Polyethylene Glycol Allergy
Autor principal: | Gelfman, Daniel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mosby-Year Book
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381617/ https://www.ncbi.nlm.nih.gov/pubmed/34438025 http://dx.doi.org/10.1016/j.echo.2021.08.010 |
Ejemplares similares
-
Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
por: Garvey, Lene H., et al.
Publicado: (2021) -
Fractionated vaccination with mRNA COVID‐19 vaccine is safe for patients with polyethylene glycol allergy
por: Mortz, Charlotte G., et al.
Publicado: (2023) -
Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis
por: Brockow, Knut, et al.
Publicado: (2021) -
Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series
por: Picard, Matthieu, et al.
Publicado: (2022) -
Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy
por: Bruusgaard-Mouritsen, Maria A., et al.
Publicado: (2022)